NCT05530421View on ClinicalTrials.gov

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 26, 2023

Primary Completion Date

March 26, 2026

Study Completion Date

March 26, 2028

Conditions
Relapsed and Refractory Multiple Myeloma
Interventions
DRUG

Selinexor

Selinexor tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.

DRUG

Venetoclax

Venetoclax tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.

DRUG

Dexamethasone

Dexamethasone tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.

Trial Locations (3)

33136

RECRUITING

University of Miami, Sylvester Comprehensive Cancer Center, Miami

33146

RECRUITING

University of Miami, Lennar Foundation Medical Center, Coral Gables

33442

RECRUITING

University of Miami, Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach

Sponsors
All Listed Sponsors
collaborator

Karyopharm Therapeutics Inc

INDUSTRY

lead

University of Miami

OTHER